Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the ...

AbbVie has put together a dream team of eight big-selling drugs that it says will end its reliance on its blockbuster Humira – which despite tougher competition could still generate peak sales ...

The patent for Humira, the world’s bestselling drug, expires in Europe today – opening the door for a host of cheaper biosimilars to hit the market. Sales of AbbVie’s Humira (adalimumab ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...

Abbvie’s management continues to work through the loss of exclusivity from Humira, switching patients to Skyrizi or Rinvoq rather than Humira biosimilars.” ...

From establishing AbbVie's first financial planning organization, to developing its diversified business strategy, to successfully navigating the end of exclusivity for Humira in the US,. Michael has ...

Abbvie’s management continues to work through the loss of exclusivity from Humira, switching patients to Skyrizi or Rinvoq rather than Humira biosimilars.” Overall, ABBV ranks 7th on our list ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best drug stocks to buy now. Large American pharmaceutical companies are showing a distinct trend ...

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for medicines in China. According to data from DealForma, as reported by CNBC, ...